IRIS
BURLONE, MICHELA Emma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 934
NA - Nord America 773
AS - Asia 250
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.965
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 770
IE - Irlanda 296
SE - Svezia 139
IT - Italia 134
DE - Germania 121
UA - Ucraina 93
CN - Cina 77
FR - Francia 72
IN - India 63
HK - Hong Kong 60
FI - Finlandia 39
SG - Singapore 34
BE - Belgio 13
GB - Regno Unito 10
VN - Vietnam 10
CZ - Repubblica Ceca 8
IR - Iran 6
KE - Kenya 5
CA - Canada 3
PL - Polonia 3
EU - Europa 2
NL - Olanda 2
RU - Federazione Russa 2
BG - Bulgaria 1
CL - Cile 1
RO - Romania 1
Totale 1.965
Salva come PNG Salva come JPEG
Città #
Dublin 293
Jacksonville 175
Chandler 89
Dearborn 82
Ann Arbor 67
Hong Kong 60
Wilmington 54
Piemonte 39
Princeton 34
Lawrence 33
Novara 28
Beijing 25
Singapore 22
San Mateo 18
Andover 14
Brussels 13
Ashburn 11
Dong Ket 10
Munich 9
Nanjing 9
Brno 8
Bremen 7
Hefei 7
Houston 7
Jinan 5
Kunming 5
Milan 5
Nairobi 5
Seattle 5
Augusta 4
Boardman 4
Helsinki 4
Leawood 4
Monmouth Junction 4
Rome 4
Turin 4
Woodbridge 4
Cassano Magnago 3
Fairfield 3
Kraków 3
Norwalk 3
Strasbourg 3
Ardabil 2
Cassano 2
Chongqing 2
Cumiana 2
Frankfurt am Main 2
Ghemme 2
Guangzhou 2
Hangzhou 2
Lucca 2
Moncalieri 2
Mülheim 2
Ningbo 2
Palermo 2
Shanghai 2
Torino 2
Verona 2
Viareggio 2
Winnipeg 2
Amsterdam 1
Bangalore 1
Baotou 1
Berlin 1
Busalla 1
Casaleggio Novara 1
Cutrofiano 1
Domodossola 1
Düsseldorf 1
Forno Canavese 1
Fuzhou 1
Gorgonzola 1
Grafing 1
Hebei 1
Irkutsk 1
Islington 1
Jiaxing 1
Kemerovo 1
Kolkata 1
Lodi 1
Minneapolis 1
Moneglia 1
Mumbai 1
Nanchang 1
Nanning 1
Nichelino 1
Olcenengo 1
Ortonovo 1
Pisa 1
Pozzuolo 1
Quinto di Treviso 1
Quzhou 1
Sacramento 1
San Giusto Canavese 1
Taiyuan 1
Taizhou 1
Taranto 1
Toronto 1
Trieste 1
Vercelli 1
Totale 1.262
Salva come PNG Salva come JPEG
Nome #
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 94
Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders 80
Influence of age on sex-related differences among patients with hepatitis C. 77
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C 75
Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis 75
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 66
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents 66
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy] 66
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 65
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 65
Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment 65
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 61
Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C 61
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C 60
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 60
IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. 59
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. 59
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients 58
Liver stiffness, not fat liver content, predicts the length of QTc interval in patients with chronic liver disease 56
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 54
Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease 54
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia 52
Interferon-stimulated gene pathways in the treatment of viral hepatitis 51
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 50
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 50
GENETIC POLYMORPHISM AT THE APOLIPOPROTEIN E LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B 47
Recent advances in HCV entry 47
Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression 44
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. 44
Toxocara encephalitis presenting with autonomous nervous system involvement 41
PANCREATOBILIARY REFLUX RESULTING IN PANCREATIC ASCITES AND CHOLEPERITONEUM AFTER GALLBLADDER PERFORATION 40
HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment 38
17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon 33
Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study 33
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 27
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 14
Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis 14
Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development 8
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 7
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 3
Totale 2.019
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.692
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.692
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020445 2 8 37 0 59 56 91 23 47 83 32 7
2020/2021273 31 4 31 3 46 23 37 3 35 11 35 14
2021/2022234 4 13 31 18 15 2 20 12 16 22 32 49
2022/2023641 60 33 41 7 44 62 17 36 307 1 23 10
2023/2024240 24 39 21 0 35 2 42 6 1 4 27 39
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 2.019